EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Advancements in Telomerase-Targeted Therapies for Glioblastoma: A Systematic Review

Giovanni Pennisi iD, Placido Bruzzaniti iD, Benedetta Burattini, Giacomo Piaser Guerrato iD, Giuseppe Maria Della Pepa iD, Carmelo Lucio Sturiale iD, Pierfrancesco Lapolla iD, Pietro Familiari iD, Biagia La Pira, Giancarlo D'Andrea iD, Alessandro Olivi, Quintino Giorgio D'Alessandris iD und 1 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25168700 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Giovanni Pennisi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy. Hauptthemen laut MEDLINE: Telomerase, Glioblastoma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is a primary CNS tumor that is highly lethal in adults and has limited treatment options. Despite advancements in understanding the GBM biology, the standard treatment for GBM has remained unchanged for more than a decade. Only 6.8% of patients survive beyond five years. Telomerase, particularly the hTERT promoter mutations present in up to 80% of GBM cases, represents a promising therapeutic target due to its role in sustaining telomere length and cancer cell proliferation. This review examines the biology of telomerase in GBM and explores potential telomerase-targeted therapies. We conducted a systematic review following the PRISMA-P guidelines in the MEDLINE/PubMed and Scopus databases, from January 1995 to April 2024. We searched for suitable articles by utilizing the terms “GBM”, “high-grade gliomas”, “hTERT” and “telomerase”. We incorporated studies addressing telomerase-targeted therapies into GBM studies, excluding non-English articles, reviews, and meta-analyses. We evaluated a total of 777 records and 46 full texts, including 36 studies in the final review. Several compounds aimed at inhibiting hTERT transcription demonstrated promising preclinical outcomes; however, they were unsuccessful in clinical trials owing to intricate regulatory pathways and inadequate pharmacokinetics. Direct hTERT inhibitors encountered numerous obstacles, including a prolonged latency for telomere shortening and the activation of the alternative lengthening of telomeres (ALT). The G-quadruplex DNA stabilizers appeared to be potential indirect inhibitors, but further clinical studies are required. Imetelstat, the only telomerase inhibitor that has undergone clinical trials, has demonstrated efficacy in various cancers, but its efficacy in GBM has been limited. Telomerase-targeted therapies in GBM is challenging due to complex hTERT regulation and inadequate inhibitor pharmacokinetics. Our study demonstrates that, despite promising preclinical results, no Telomerase inhibitors have been approved for GBM, and clinical trials have been largely unsuccessful. Future strategies may include Telomerase-based vaccines and multi-target inhibitors, which may provide more effective treatments when combined with a better understanding of telomere dynamics and tumor biology. These treatments have the potential to be integrated with existing ones and to improve the outcomes for patients with GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TelomeraseGlioblastomaHumansBrain NeoplasmsMolecular Targeted TherapyAntineoplastic AgentsTelomereAnimals

Stichwörter der Autor:innen

brain tumorglioblastoma (GBM)hTERT inhibitorsmulti-target inhibitorstelomerase-targeted therapies

Substanzen

TelomeraseTERT protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
  • Department of Neurosurgery, F. Spaziani Hospital, 03100 Frosinone, Italy.
  • Department of Human Neurosciences, Division of Neurosurgery, Policlinico Umberto I University Hospital, Sapienza, University of Rome, 00157 Rome, Italy.
  • Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX1 2JD, UK.

ORCID-Profile: Giovanni Pennisi, Placido Bruzzaniti, Giacomo Piaser Guerrato, Giuseppe Maria Della Pepa, Carmelo Lucio Sturiale, Pierfrancesco Lapolla, Pietro Familiari, Giancarlo D'Andrea, Quintino Giorgio D'Alessandris, Nicola Montano

Zitieren

APA

Pennisi, G., Bruzzaniti, P., Burattini, B., Piaser Guerrato, G., Della Pepa, G. M., Sturiale, C. L., Lapolla, P., Familiari, P., La Pira, B., D'Andrea, G., Olivi, A., D'Alessandris, Q. G., & Montano, N. (2024). Advancements in Telomerase-Targeted Therapies for Glioblastoma: A Systematic Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25168700

Vancouver

Pennisi G, Bruzzaniti P, Burattini B, Piaser Guerrato G, Della Pepa GM, Sturiale CL, et al. Advancements in Telomerase-Targeted Therapies for Glioblastoma: A Systematic Review. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25168700

BibTeX
@article{Pennisi2024,
  author = {Pennisi, Giovanni and Bruzzaniti, Placido and Burattini, Benedetta and Piaser Guerrato, Giacomo and Della Pepa, Giuseppe Maria and Sturiale, Carmelo Lucio and Lapolla, Pierfrancesco and Familiari, Pietro and La Pira, Biagia and D'Andrea, Giancarlo and Olivi, Alessandro and D'Alessandris, Quintino Giorgio and Montano, Nicola},
  title = {Advancements in Telomerase-Targeted Therapies for Glioblastoma: A Systematic Review},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25168700}
}
Kostenlos starten →